All Eyes Are on IL-15 in Early Phase Studies

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

Related Keywords

United States ,Washington ,New Jersey ,Hackensack ,American ,Martine Gutierrez , ,Gastrointestinal Oncology Program ,Exchange Commission ,John Theurer Cancer Center ,Immunitybio Inc ,American Society Of Clinical Oncology Annual Meeting ,Yel Research ,Georgetown Lombardi Cancer Center ,Phasei Diseases Group ,Drug Discovery Phasei Program ,Monitoring Committee ,Phasei Program ,Hackensack Meridian School ,Protocol Review ,Terror With ,Prescription Drug User Fee Act ,Chemistry Manufacturing ,Clinical Oncology Annual ,Accessed February ,United States Securities ,Il 15 ,Fusion Protein Sar445877 ,Sar445877 ,Il 15 Targeted Agents ,D ,First In Human Phase 1 2 Trial Nct05584670 ,